Drug Type Trispecific T-cell engager (TriTE) |
Synonyms CC312 |
Target |
Action inhibitors, agonists, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Haemolytic Anaemias | Phase 1 | China | 08 Nov 2024 | |
Idiopathic Inflammatory Myopathies | Phase 1 | China | 08 Nov 2024 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | 08 Nov 2024 | |
Rheumatoid Arthritis | Phase 1 | China | 08 Nov 2024 | |
Scleroderma, Systemic | Phase 1 | China | 08 Nov 2024 | |
Systemic Lupus Erythematosus | Phase 1 | China | 08 Nov 2024 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 07 Aug 2023 | |
B-cell lymphoma refractory | Phase 1 | China | 07 Aug 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | China | 07 Aug 2023 | |
CD19 Positive B-Cell Leukemia | Phase 1 | China | 07 Aug 2023 |
Not Applicable | - | owmvrggjcp(hrgrohwknx) = ddarzklimd gkmitbionw (mzlvxflfep ) | - | 28 Apr 2025 |